ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: TH-PO165

Improvement of Clinical Outcome in Kidney Diseases via the On-line Thai Glomerular Disease Registry: Minimal Change Disease

Session Information

Category: Glomerular

  • 1005 Clinical Glomerular Disorders

Authors

  • Pattharanitima, Pattharawin, Thammasat University, Pathumthani, Thailand
  • Chawanasuntorapoj, Ratana, Siriraj Hospital, Bangkok, Thailand
  • Pichaiwong, Warangkana, RAJAVITHI HOSPITAL, Bangkok, Thailand
  • Sangthawan, Pornpen, Prince of Songkla University Hospital, Songkhla, Thailand
  • Tantranont, Ngoentra, Siriraj Hospital, Mahidol University, Bangkok, Thailand
  • Cheunsuchon, Boonyarit, Siriraj hospital, Bangkok, Thailand

Group or Team Name

  • Thai Glomerular Disease Collaborative Network (TGCN)
Background

The data on prevalence, clinical characteristics and outcomes of minimal change disease (MCD) in Thailand is sparse. The available data came from few medical schools which might not represent the entire Thai population. The Thai Glomerular Disease Collaborative Network (TGCN) was established to determine the prevalence, clinical characteristics, outcomes and prognosis in Thai glomerular disease patients.

Methods

The data collected prospectively from TGCN included adult patients with biopsy-proven glomerular disease from institutes in Thailand participating in TGCN from July 2014 to March 2017. The clinical and renal pathology characteristics, treatment regimens at the time of renal biopsy, clinical outcomes, and complications at 24, 48 and every 48 weeks after renal biopsy were obtained via online data collection forms.

Results

Among 1,556 patients, 115 (7.4%) had MCD. At baseline, 53% of MCD patients were male, the mean age was 46.5 + 17.2 years, median serum creatinine (sCr) was 1.02 mg/dL (0.5-10.7), mean urine protein creatinine ratio (UPCR) was 5.99±4.72 g/g.Cr, mean serum albumin (sAlb) was 2.4±0.9 g/dL, and mean serum cholesterol (sChol) was 422±194 mg/dL. At 24 weeks, 62% had complete remission, and 19% had partial remission. Median time to remission was 1.5 months. The odd ratio of remission was 3.13 in patients with UPCR >5 (P=0.047). The age, sAlb, sChol, sCr at time of biopsy and pathological characteristics were not different between remission and non-remission groups. The 1.5% of them had doubling serum creatinine, none of them developed ESRD and 1.4% of patient died during the study.

Conclusion

Conclusions: The outcome of the adults with MCD was excellent. The patients with UPCR >5 at baseline had more favorable outcome.

Funding: Health Systems Research Institute and Nephrology Society of Thailand support

Funding

  • Private Foundation Support